Population-based incidence and serotype distribution of invasive pneumococcal disease prior to introduction of conjugate pneumococcal vaccine in Bangladesh.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
07
2019
accepted:
23
01
2020
entrez:
14
2
2020
pubmed:
14
2
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV-10) in 2015. We measured population-based incidence of invasive pneumococcal disease (IPD) prior to introduction of PCV-10 to provide a benchmark against which the impact of PCV-10 can be assessed. We conducted population, facility and laboratory-based surveillance in children 0-59 months of age in three rural sub-districts of Sylhet district of Bangladesh from January 2014 to June 2015. All children received two-monthly home visits with one week recall for morbidity and care seeking. Children attending the three Upazilla Health Complexes (UHC, sub-district hospitals) in the surveillance area were screened for suspected IPD. Blood samples were collected from suspected IPD cases for culture and additionally, cerebrospinal fluid (CSF) was collected from suspected meningitis cases for culture and molecular testing. Pneumococcal isolates were serotyped by Quellung. Serotyping of cases detected by molecular testing was done by sequential multiplex polymerase chain reaction. Children under surveillance contributed to 126,657 child years of observations. Sixty-three thousand three hundred eighty-four illness episodes were assessed in the UHCs. Blood specimens were collected from 8,668 suspected IPD cases and CSF from 177 suspected meningitis cases. Streptococcus pneumoniae was isolated from 46 cases; 32 (70%) were vaccine serotype. The population-based incidence of IPD was 36.3/100,000 child years of observations. About 80% of the cases occurred in children below two years of age. IPD was common in rural Bangladesh suggesting the potential benefit of an effective vaccine. Measurement of the burden of IPD requires multiple surveillance modalities.
Sections du résumé
BACKGROUND
Bangladesh introduced the 10-valent pneumococcal conjugate vaccine (PCV-10) in 2015. We measured population-based incidence of invasive pneumococcal disease (IPD) prior to introduction of PCV-10 to provide a benchmark against which the impact of PCV-10 can be assessed.
METHODS
We conducted population, facility and laboratory-based surveillance in children 0-59 months of age in three rural sub-districts of Sylhet district of Bangladesh from January 2014 to June 2015. All children received two-monthly home visits with one week recall for morbidity and care seeking. Children attending the three Upazilla Health Complexes (UHC, sub-district hospitals) in the surveillance area were screened for suspected IPD. Blood samples were collected from suspected IPD cases for culture and additionally, cerebrospinal fluid (CSF) was collected from suspected meningitis cases for culture and molecular testing. Pneumococcal isolates were serotyped by Quellung. Serotyping of cases detected by molecular testing was done by sequential multiplex polymerase chain reaction.
RESULTS
Children under surveillance contributed to 126,657 child years of observations. Sixty-three thousand three hundred eighty-four illness episodes were assessed in the UHCs. Blood specimens were collected from 8,668 suspected IPD cases and CSF from 177 suspected meningitis cases. Streptococcus pneumoniae was isolated from 46 cases; 32 (70%) were vaccine serotype. The population-based incidence of IPD was 36.3/100,000 child years of observations. About 80% of the cases occurred in children below two years of age.
DISCUSSION
IPD was common in rural Bangladesh suggesting the potential benefit of an effective vaccine. Measurement of the burden of IPD requires multiple surveillance modalities.
Identifiants
pubmed: 32053640
doi: 10.1371/journal.pone.0228799
pii: PONE-D-19-21458
pmc: PMC7018078
doi:
Substances chimiques
10-valent pneumococcal conjugate vaccine
0
DNA, Bacterial
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0228799Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Hum Vaccin. 2011 Jan-Feb;7 Suppl:211-6
pubmed: 21546795
PLoS One. 2012;7(3):e32134
pubmed: 22479314
Pediatr Infect Dis J. 1998 Jan;17(1):23-8
pubmed: 9469390
Lancet. 2009 Aug 1;374(9687):393-403
pubmed: 19647607
J Trop Pediatr. 2011 Jun;57(3):192-6
pubmed: 20736384
PLoS One. 2014 May 05;9(5):e96282
pubmed: 24798424
Pneumonia (Nathan). 2017 Mar 25;9:6
pubmed: 28702308
Gates Open Res. 2018 Apr 26;2:21
pubmed: 29984359
Pediatr Infect Dis J. 2016 Jun;35(6):655-61
pubmed: 26658530
Am J Trop Med Hyg. 2016 Sep 7;95(3):680-2
pubmed: 27430538
Jpn J Infect Dis. 2017 Sep 25;70(5):495-501
pubmed: 28367876
Lancet. 2009 Sep 12;374(9693):893-902
pubmed: 19748398
Clin Infect Dis. 2017 Nov 13;65(11):1813-1818
pubmed: 29020195
Lancet. 2006 Feb 11;367(9509):482-8
pubmed: 16473125
Pediatr Infect Dis J. 2002 Dec;21(12):1115-23
pubmed: 12488660
Pediatr Infect Dis J. 2004 Jul;23(7):642-9
pubmed: 15247603
Lancet. 2005 Mar 26-Apr 1;365(9465):1139-46
pubmed: 15794968
PLoS One. 2017 May 9;12(5):e0177113
pubmed: 28486544
Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S103-13
pubmed: 19191605
Hum Vaccin Immunother. 2016;12(2):285-92
pubmed: 26905679
Expert Rev Vaccines. 2018 Jun;17(6):479-493
pubmed: 29241390
Wkly Epidemiol Rec. 2007 Mar 23;82(12):93-104
pubmed: 17380597
BMC Med. 2017 Jun 7;15(1):113
pubmed: 28592303
PLoS One. 2015 Sep 02;10(8):e0135270
pubmed: 26332848
Vaccine. 2013 Aug 28;31(38):4200-8
pubmed: 23684826
PLoS One. 2018 Jan 5;13(1):e0190687
pubmed: 29304066